WO2009070164A1 - Amélioration de la vigueur par administration de dérivés de pyrimidine - Google Patents

Amélioration de la vigueur par administration de dérivés de pyrimidine Download PDF

Info

Publication number
WO2009070164A1
WO2009070164A1 PCT/US2007/085765 US2007085765W WO2009070164A1 WO 2009070164 A1 WO2009070164 A1 WO 2009070164A1 US 2007085765 W US2007085765 W US 2007085765W WO 2009070164 A1 WO2009070164 A1 WO 2009070164A1
Authority
WO
WIPO (PCT)
Prior art keywords
dihydro
oxo
pyrro
pyrimidine
methyl
Prior art date
Application number
PCT/US2007/085765
Other languages
English (en)
Inventor
Kiminobu Sugaya
Angel Alvarez
Original Assignee
University Of Central Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Central Florida filed Critical University Of Central Florida
Priority to EP07854812.0A priority Critical patent/EP2324023B1/fr
Priority to PCT/US2007/085765 priority patent/WO2009070164A1/fr
Priority to CA2670341A priority patent/CA2670341C/fr
Publication of WO2009070164A1 publication Critical patent/WO2009070164A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Abstract

L'invention concerne des procédés d'amélioration de la vigueur globale d'un sujet et/ou de la vigueur de tissus cibles d'un sujet. L'utilisation de dérivés de pyrimidine qui agissent en stimulant la prolifération de cellules souches est donnée en exemple ici. En plus d'augmenter la vigueur, de tels agents de prolifération de cellules souches (SCPA) peuvent être utilisés pour augmenter et/ou améliorer le résultat d'autres thérapies et peuvent être utilisés pour des applications psychiatriques. L'augmentation de la vigueur chez des sujets n'est pas nécessairement ciblée au traitement d'une maladie. Les procédés peuvent ainsi inclure l'administration à des animaux cliniquement sains.
PCT/US2007/085765 2006-11-28 2007-11-28 Amélioration de la vigueur par administration de dérivés de pyrimidine WO2009070164A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07854812.0A EP2324023B1 (fr) 2006-11-28 2007-11-28 Amélioration de la vigueur par administration de dérivés de pyrimidine
PCT/US2007/085765 WO2009070164A1 (fr) 2007-11-28 2007-11-28 Amélioration de la vigueur par administration de dérivés de pyrimidine
CA2670341A CA2670341C (fr) 2006-11-28 2007-11-28 Amelioration de la vigueur par administration de derives de pyrimidine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/085765 WO2009070164A1 (fr) 2007-11-28 2007-11-28 Amélioration de la vigueur par administration de dérivés de pyrimidine

Publications (1)

Publication Number Publication Date
WO2009070164A1 true WO2009070164A1 (fr) 2009-06-04

Family

ID=40678878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/085765 WO2009070164A1 (fr) 2006-11-28 2007-11-28 Amélioration de la vigueur par administration de dérivés de pyrimidine

Country Status (1)

Country Link
WO (1) WO2009070164A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190183898A1 (en) * 2016-06-06 2019-06-20 University Of Central Florida Research Foundation, Inc. Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US4364923A (en) 1972-04-20 1982-12-21 Allen & Hanburs Limited Chemical compounds
US4959368A (en) 1986-02-24 1990-09-25 Mitsui Petrochemical Industries Ltd. Therapeutic agent for neurological diseases
US5033352A (en) 1989-01-19 1991-07-23 Yamaha Corporation Electronic musical instrument with frequency modulation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5976523A (en) 1995-05-16 1999-11-02 Mitsui Pharmaceuticals, Inc. Method for healing compromised tissues using pyrimidine derivatives
US20030113912A1 (en) * 1996-08-13 2003-06-19 Fujisawa Pharmaceutical Co. Ltd. Hematopoietic stem cell proliferating agents
US20030139410A1 (en) * 2002-01-14 2003-07-24 Kiminobu Sugaya Use of modified pyrimidine compounds to promote stem cell migration and proliferation
US20060003919A1 (en) * 2004-05-26 2006-01-05 Nicolas Fortunel Cosmetic/dermatological applications of LIF
US20060147435A1 (en) * 2004-12-30 2006-07-06 Moon Randall T Methods for regulation of stem cells
US20060257449A1 (en) * 2005-05-16 2006-11-16 Didier Billy Methods, compositions, systems, and devices for bone fusion

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US4364923A (en) 1972-04-20 1982-12-21 Allen & Hanburs Limited Chemical compounds
US4414209A (en) 1972-04-20 1983-11-08 Allen & Hanburys Limited Micronized aerosol steroids
US4959368A (en) 1986-02-24 1990-09-25 Mitsui Petrochemical Industries Ltd. Therapeutic agent for neurological diseases
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033352A (en) 1989-01-19 1991-07-23 Yamaha Corporation Electronic musical instrument with frequency modulation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5976523A (en) 1995-05-16 1999-11-02 Mitsui Pharmaceuticals, Inc. Method for healing compromised tissues using pyrimidine derivatives
US20030113912A1 (en) * 1996-08-13 2003-06-19 Fujisawa Pharmaceutical Co. Ltd. Hematopoietic stem cell proliferating agents
US20030139410A1 (en) * 2002-01-14 2003-07-24 Kiminobu Sugaya Use of modified pyrimidine compounds to promote stem cell migration and proliferation
US20060003919A1 (en) * 2004-05-26 2006-01-05 Nicolas Fortunel Cosmetic/dermatological applications of LIF
US20060147435A1 (en) * 2004-12-30 2006-07-06 Moon Randall T Methods for regulation of stem cells
US20060257449A1 (en) * 2005-05-16 2006-11-16 Didier Billy Methods, compositions, systems, and devices for bone fusion

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING COMPANY
CLARK ET AL., MOLEC. BIOCHEM. PARASITOL., vol. 17, 1994, pages 129
DOMINGUEZ ET AL., J. MED. CHEM., vol. 40, 1997, pages 2726 - 2732
ENGEL ET AL., J. EXP. MED., vol. 188, no. 4, 1998, pages 725 - 734
LECHNER ET AL.: "Stem/progenitor cells derived from adult tissues: potential for the treatment of diabetes mellitus", AM J PHYSIOL ENDOCRINOL METAB, vol. 284, February 2003 (2003-02-01), pages E259 - E266, XP009056159 *
LI ET AL., J. MED. CHEM., vol. 38, 1995, pages 5031
RING ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 3583 - 3587
ROSENTHAL ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 40, no. 7, 1996, pages 1600 - 1603
See also references of EP2324023A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190183898A1 (en) * 2016-06-06 2019-06-20 University Of Central Florida Research Foundation, Inc. Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions
US10751340B2 (en) * 2016-06-06 2020-08-25 University Of Central Florida Research Foundation, Inc. Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions

Similar Documents

Publication Publication Date Title
US20090022694A1 (en) Sirt1 inhibition
US20100330063A1 (en) Stem-like cells, method for de-differentiating mammalian somatic cells into stem-like cells, and method for differentiating stem-like cells
US11505572B2 (en) Therapeutics for the treatment of glaucoma
US20120009152A1 (en) Nitric oxide donors for treatment of disease and injury
JP2008518922A (ja) 緑内障性の網膜障害および眼科疾患を処置するためのｊｕｎｎ末端キナーゼのインヒビター
US8865723B2 (en) Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
US20200246334A1 (en) Vigor enhancement via administration of pyrimidine derivatives
TW202216988A (zh) 源自滑膜之間葉系幹細胞之製造方法及關節治療用細胞製劑之製造方法
KR20070040326A (ko) 백내장, 황반 변성 및 다른 안과 질환의 개선
AU745028B2 (en) Secondary cataract inhibitor
CA2670341C (fr) Amelioration de la vigueur par administration de derives de pyrimidine
WO2009070164A1 (fr) Amélioration de la vigueur par administration de dérivés de pyrimidine
KR20160109019A (ko) 지방-유래 줄기세포를 함유하는 정맥혈관 투여를 통한 아토피 피부염의 예방 또는 치료용 조성물
US11833148B2 (en) Methods for treating or limiting development of cardiovascular disease-related neurological disorders
US20230414666A1 (en) Stem cell-produced microvesicles for treating tendon pathologies
EP4342479A1 (fr) Composition contenant une cellule souche à fonction renforcée pour la prévention ou le traitement de la dermatite atopique
WO1995022323A1 (fr) Procedes pour limiter la production de radicaux libres due a des cellules inflammatoires
TW200829261A (en) Method for controlling angiogenesis in animals
AU2006204317A2 (en) Rigidified compounds for modulating heparanase activity
JP2020137518A (ja) 添加剤
TW202039834A (zh) 包含克隆幹細胞的用於預防或治療特應性皮炎的藥學組合物
KR20020023941A (ko) 산화방지성 비타민 ｂ6 유사체
US20180117088A1 (en) Composition for treating articular cartilage defects
US20230310490A1 (en) Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
Picazo et al. Current Advances in Mesenchymal Stem Cell Therapies Applied to Wounds and Skin, Eye, and Neuromuscular Diseases in Companion Animals

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2670341

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2007854812

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007854812

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07854812

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE